Novavax Nuvaxovid COVID-19 vaccine received expanded authorization in Canada as a booster in adults
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
On Nov. 18, 2022, the World Health Organisation for Animal Health (WHO) announced that Peru had reported its…
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
On Nov. 5, 2022, the U.S. Department of Agriculture’s (USDA) Animal Plant Health Inspection Service (APHIS) confirmed the…
On Nov. 4, 2022, the Oregon Department of Agriculture (ODA) and the U.S. Department of Agriculture’s (USDA) Animal…
On Nov. 4, 2022, Moderna announced that Health Canada had authorized the use of its BA.4/BA.5 Omicron-targeting bivalent…
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800…
On Oct. 27, 2022, the U.S. Department of Agriculture’s Animal Plant Health Inspection Service (APHIS) confirmed the presence…
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
On Oct. 18, 2022, global leaders confirmed US$ 2.6 billion in funding toward the Global Polio Eradication Initiative’s…
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, announced they had mutually agreed to cancel remaining…
On Oct. 13, 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination…
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
On Oct. 10, 2022, Novavax announced that Switzerland’s Federal Office of Public Health had recommended Nuvaxovid (NVX-CoV2373) as…
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada had authorized COMIRNATY Original & Omicron BA.4/BA.5…
On Oct. 7, 2022, the U.S. Department of Agricultures Animal Plant Health Inspection Service (APHIS) confirmed the presence…
On Oct. 6, 2022, researchers in Japan released a study that described the development and application of the…
On Oct. 4, 2022, the United States Department of Agriculture’s (USDA) Agricultural Research Service (ARS), Southeast Poultry Research…
On Sept. 28, 2022, Moderna announced that the European Medicines Agency (EMA) had accepted a variation for the…
On Sept. 28, 2022, the Oregon Department of Agriculture and the U.S. Department of Agriculture’s Animal Plant Health…
On Sept. 27, 2022, the National Institutes of Health (NIH) announced that a large international study had confirmed…
On Sept. 27, 2022, Novavax announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine were…
On Sept. 16, 2022, Novavax announced that the Taiwan Food and Drug Administration had granted expanded emergency use…